List of Excipients in Branded Drug OZURDEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	OZURDEX	dexamethasone	0023-3348	DL-LACTIDE AND GLYCOLIDE

OZURDEX Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 25, 2026

OZURDEX is a biodegradable intravitreal dexamethasone implant containing 0.7 mg dexamethasone in a poly(lactic-co-glycolic acid), or PLGA, matrix. Its commercial value is driven less by conventional excipients than by the excipient’s role as a drug-delivery system. PLGA controls release, supports a preservative-free solid implant, and enables administration through a dedicated intravitreal applicator. The strongest commercial opportunities are in PLGA grade control, implant manufacturing, applicator technology, ophthalmic 505(b)(2) products, and differentiated sustained-release corticosteroid systems.

What excipients protect the OZURDEX formulation?

OZURDEX uses PLGA as the principal formulation excipient and release-controlling matrix.

Attribute	OZURDEX profile
Active ingredient	Dexamethasone
Dose	0.7 mg per implant
Dosage form	Biodegradable intravitreal implant
Primary excipient	PLGA polymer
Administration	Single-use intravitreal applicator
Preservatives	None in the implant formulation
Release duration	Up to approximately six months, depending on indication and clinical response
Manufacturer	AbbVie through the Allergan ophthalmology business
FDA pathway	New drug application, 2009 initial approval
Principal formulation technology	Biodegradable polymer matrix

The FDA prescribing information identifies the implant as a biodegradable matrix containing dexamethasone and PLGA. The implant is inserted into the vitreous through a specialized applicator rather than delivered as a conventional liquid injection.[1]

The excipient is therefore functional, not merely compositional. PLGA affects:

• Drug loading and content uniformity
• Implant geometry and mechanical integrity
• Hydration and polymer erosion
• Initial drug release
• Duration of corticosteroid exposure
• Degradation-product profile
• Sterilization compatibility
• Applicator performance
• Manufacturing yield

This structure creates a higher technical barrier than a conventional dexamethasone solution or suspension.

How does PLGA control OZURDEX drug release?

PLGA controls dexamethasone release through water penetration, polymer hydrolysis, matrix erosion, and diffusion. The commercial performance of the implant depends on polymer attributes that may vary between suppliers and manufacturing lots.

Key variables include:

PLGA variable	Commercial and regulatory effect
Lactide:glycolide ratio	Changes hydrolysis rate and release duration
Molecular weight	Affects mechanical strength and degradation
Molecular-weight distribution	Influences batch-to-batch release variability
End-group chemistry	Can affect water uptake and degradation
Residual monomer or solvent	Affects purity and safety profile
Particle or polymer morphology	Influences drug dispersion and release
Moisture content	Can accelerate polymer degradation
Sterilization exposure	May alter molecular weight and implant performance

For an OZURDEX-type product, the excipient specification must control both chemical and physical attributes. Standard pharmaceutical-grade PLGA may not be sufficient if it does not match the required degradation profile, mechanical properties, residual-solvent limits, and sterilization behavior.

Which PLGA grades create the strongest opportunity?

The most commercially relevant opportunity is a controlled ophthalmic PLGA platform rather than a generic catalog polymer.

Potential differentiators include:

1. Narrow molecular-weight distribution.
2. Low residual solvent and low residual monomer content.
3. Controlled end-group chemistry.
4. Tight moisture specifications.
5. Consistent degradation kinetics.
6. Prequalified sterilization stability.
7. Documentation suitable for FDA drug-master-file support.
8. Supply continuity for small-volume ophthalmic manufacturing.

A supplier that can provide qualified PLGA with validated release behavior can become embedded in a sponsor’s formulation and manufacturing process. That relationship may be difficult to displace because a polymer change can trigger comparability work, stability studies, nonclinical testing, and clinical bridging.

What commercial opportunities exist around OZURDEX excipients?

The largest opportunities are in enabling materials, manufacturing systems, and follow-on drug-delivery products.

Ophthalmic PLGA supply

A specialized supplier could sell:

• Custom PLGA grades
• Contract polymer development
• Polymer characterization
• Residual-solvent testing
• Degradation and release testing
• Sterilization qualification
• Regulatory documentation
• Lot-release support

The value proposition is higher than that of ordinary excipient distribution because the polymer is directly linked to dose release and clinical exposure.

Implant manufacturing

Contract development and manufacturing organizations can support:

• Drug-polymer blending
• Extrusion or molding
• Implant cutting and dimensional control
• Drug-content uniformity
• Surface inspection
• Moisture-controlled packaging
• Sterile manufacturing
• Applicator loading
• Final-device assembly

The manufacturing process is a potential barrier because the product is a drug-device combination with a small implant and a delivery system. Process knowledge may be protected through trade secrets even where foundational patents have expired.

Applicator components

The applicator creates a separate opportunity in:

• Needle geometry
• Implant retention
• Deployment force
• Anti-premature-release mechanisms
• Tip protection
• Sterile barrier packaging
• Single-use device assembly

A competing implant may require a different applicator, but the device must still deliver the implant into the vitreous with consistent placement and acceptable force. Device performance can affect usability, dosing accuracy, and product liability exposure.

New sustained-release ophthalmic products

The PLGA platform can be adapted for:

• Dexamethasone in other ocular indications
• Triamcinolone or other corticosteroids
• Anti-inflammatory combinations
• Postoperative inflammation
• Uveitis
• Retinal vascular disease
• Drug delivery after ocular surgery

The opportunity is constrained by intraocular safety. Polymer degradation products, implant migration, intraocular pressure elevation, cataract risk, inflammation, and retinal effects must be characterized for each product.

What FDA indications and regulatory protections apply to OZURDEX?

The FDA approved OZURDEX in 2009 for macular edema following branch retinal vein occlusion or central retinal vein occlusion. FDA later expanded the product’s use to noninfectious uveitis affecting the posterior segment of the eye and diabetic macular edema.[1,2]

FDA milestone	Event
2009	Initial FDA approval for macular edema following BRVO or CRVO
2010	Approval for noninfectious uveitis affecting the posterior segment
2014	Approval for diabetic macular edema
Product type	Biodegradable intravitreal corticosteroid implant
Regulatory complexity	Drug-device combination with localized sustained release

OZURDEX received orphan-drug designation for noninfectious uveitis affecting the posterior segment. Orphan exclusivity is indication-specific and does not create a general six-year monopoly over every OZURDEX use.[2]

The product’s pediatric exclusivity and other regulatory protections must be evaluated from the applicable FDA exclusivity records and current Orange Book entries. Patent expiration and regulatory exclusivity are separate rights.

When does OZURDEX lose exclusivity?

OZURDEX’s original regulatory exclusivity has largely elapsed, but market entry depends on patents, product-specific FDA requirements, and the technical difficulty of demonstrating equivalence.

The relevant protection layers are:

1. New drug exclusivity.
2. Orphan-drug exclusivity for the qualifying indication.
3. Formulation and implant patents.
4. Applicator and device patents.
5. Method-of-use patents.
6. Manufacturing-process protection.
7. Trade secrets involving polymer processing and implant performance.

The original formulation patent estate included U.S. patents directed to biodegradable ocular implants and related delivery technology. Public patent databases identify patents associated with the underlying technology, including U.S. Patent No. 7,767,830, titled “Biodegradable implants for treating ocular conditions.” Patent status, terminal disclaimers, patent-term adjustments, continuations, and Orange Book listing status must be assessed from current USPTO and FDA records rather than inferred from the original grant date.[3,4]

A patent’s expiration does not automatically create an immediate generic launch opportunity. FDA approval requirements can remain difficult where the reference product is a biodegradable implant rather than a conventional injectable formulation.

What patents protect OZURDEX?

The relevant patent categories are broader than a single composition patent.

Implant composition patents

These can cover:

• Dexamethasone dispersed in PLGA
• Specific polymer ratios
• Polymer molecular-weight ranges
• Implant dimensions
• Drug loading
• Release profiles
• Biodegradable ocular matrices

Method-of-use patents

Potential claims may cover treatment of:

• Diabetic macular edema
• Macular edema following retinal vein occlusion
• Posterior-segment noninfectious uveitis
• Postoperative ocular inflammation
• Specific dosing intervals
• Repeat administration schedules

Method-of-use protection is most relevant where a generic sponsor seeks a label that includes protected indications. A section viii carve-out may reduce infringement exposure for some uses, but it may not eliminate risks tied to product labeling, physician behavior, or non-carved indications.

Applicator and device patents

Device claims may cover:

• Implant storage
• Implant positioning
• Needle deployment
• Single-use actuation
• Sterile packaging
• Implant retention and release

Manufacturing patents and trade secrets

Manufacturing protection may address:

• Polymer-drug mixing
• Implant extrusion
• Drying
• Cutting
• Dimensional tolerances
• Sterilization
• Loading into the applicator

Trade secrets can remain commercially important after patent expiration because the critical process window may not be fully disclosed in a patent.

How many patents cover OZURDEX?

The answer depends on whether the analysis includes only FDA Orange Book-listed patents or the broader patent family.

For commercial launch analysis, the correct hierarchy is:

Patent group	Relevance
Orange Book-listed patents	Direct relevance to ANDA certification and Paragraph IV litigation
Related formulation patents	May support separate infringement claims
Device patents	Relevant to applicator or combination-product design
Method-of-use patents	Relevant to label scope and indication carve-outs
Foreign patents	Relevant to non-U.S. launch timing
Expired patents	Technically informative but not usually launch-blocking
Pending applications	Potential future risk, subject to prosecution outcome

The FDA Orange Book is the controlling source for patents listed against the approved reference product. A current due-diligence review should distinguish active listed patents from expired patents, delisted patents, unlisted related patents, and patents covering only methods of use.[4]

Are generic companies challenging OZURDEX?

OZURDEX is vulnerable to follow-on competition, but an ANDA is more complex than a conventional dexamethasone ophthalmic product.

A generic sponsor would likely need to address:

• Same active ingredient and strength
• Same route of administration
• Comparable implant dimensions
• Equivalent or sufficiently comparable release characteristics
• Drug-content uniformity
• Biodegradation profile
• Sterility
• Applicator functionality
• Intraocular safety
• Labeling and indication carve-outs

A Paragraph IV challenge could target listed patents covering the implant, delivery system, or method of use. The commercial attractiveness of such a challenge depends on the cost of bioequivalence development, patent-term remaining, expected launch timing, and the probability of substitutable pharmacy-level uptake.

No reliable commercial conclusion should be drawn from the mere absence of a widely publicized Paragraph IV case. Patent challenges may be confidential before filing, and some sponsors may pursue a 505(b)(2) strategy instead of an ANDA.

What generic entry risks exist for OZURDEX?

ANDA risk

An ANDA sponsor faces a technical equivalence problem. For a biodegradable implant, the FDA may scrutinize release testing and device performance more closely than it would for a conventional solution.

505(b)(2) risk

A 505(b)(2) sponsor could seek approval for a modified dexamethasone implant or a different biodegradable matrix while relying partly on FDA findings for dexamethasone. This route may support:

• A different polymer composition
• A different implant size
• A different release duration
• A revised applicator
• A narrower or broader indication
• A differentiated dosing interval

The 505(b)(2) route can avoid some ANDA equivalence constraints, but it can create clinical and patent-certification requirements.

Biosimilar risk

Biosimilar competition is not the primary risk. OZURDEX contains a chemically synthesized small-molecule corticosteroid, not a biologic. Competitors would generally pursue generic, hybrid, or 505(b)(2) pathways rather than a biosimilar application.

What formulations could compete with OZURDEX?

Product concept	Competitive advantage	Main barrier
Generic dexamethasone PLGA implant	Direct substitution potential	Equivalence and patent risk
Longer-duration implant	Fewer injections	Safety, dose control, polymer degradation
Shorter-duration implant	Better titration	Reduced adherence benefit
Injectable biodegradable microparticles	Less device complexity	Dose dispersion and ocular tolerability
Nonbiodegradable implant	Extended delivery	Removal procedure and surgical burden
Steroid-eluting ocular insert	Easier placement in some settings	Retention, comfort, and migration
Combination implant	Broader disease coverage	Compatibility and regulatory complexity
Sustained-release postoperative product	Large surgical market	Crowded competitive field

The best commercial whitespace is a product that preserves the clinical benefit of sustained steroid delivery while improving one of four attributes: duration control, applicator simplicity, safety, or retreatment flexibility.

How does OZURDEX compare with competing ocular corticosteroid products?

Product	Active ingredient	Delivery form	Duration profile	Competitive position
OZURDEX	Dexamethasone	Biodegradable intravitreal implant	Approximately several months	Strong localized delivery and established indications
ILUVIEN	Fluocinolone acetonide	Nonbiodegradable intravitreal implant	Multi-year profile	Longer duration, different safety and patient-selection profile
YUTIQ	Fluocinolone acetonide	Nonbiodegradable intravitreal implant	Up to approximately three years	Uveitis-focused sustained delivery
XIPERE	Triamcinolone acetonide	Suprachoroidal injectable suspension	Procedure-linked delivery	Different anatomical target and administration method
Intravitreal triamcinolone	Triamcinolone acetonide	Injectable suspension	Shorter and variable	Lower technology barrier, broader off-label use

OZURDEX occupies a middle position between short-acting steroid injections and long-duration nonbiodegradable implants. Its biodegradable matrix avoids surgical removal, while its duration is shorter than fluocinolone implants.

What licensing deals and partnerships create opportunity?

The most realistic licensing targets are platform and supply agreements rather than direct licensing of the OZURDEX brand.

Potential deal structures include:

• Exclusive ophthalmic rights to a PLGA implant platform
• Polymer supply agreements with minimum-volume commitments
• Co-development of a follow-on dexamethasone implant
• Contract manufacturing of implants and applicators
• Regional commercialization rights
• Device licensing for a prefilled or automated applicator
• Drug-master-file support for a qualified PLGA grade
• Acquisition of a formulation or ocular-delivery patent portfolio

An excipient supplier can capture value through a long-term supply agreement if its polymer is embedded in the sponsor’s regulatory dossier. A technology owner can seek milestone payments, development funding, royalties, or manufacturing margins.

What is the revenue exposure associated with OZURDEX?

OZURDEX revenue is exposed to four commercial variables:

1. Retreatment frequency.
2. Reimbursement for the procedure and product.
3. Competition from anti-VEGF therapy and other steroids.
4. Generic or 505(b)(2) entry.

The product’s commercial resilience comes from its established physician familiarity, localized delivery, and approved use across retinal edema and posterior-segment uveitis. The main threats are steroid-related adverse events, intraocular pressure management, cataract risk, reimbursement pressure, and longer-duration alternatives.

Exact current revenue should be taken from AbbVie’s latest annual and quarterly filings. OZURDEX may be reported within a broader ophthalmology portfolio rather than as a separately disclosed product line.[5]

How strong is the OZURDEX patent estate?

The estate is technically meaningful but should not be treated as uniformly strong across all claim categories.

Protection layer	Relative strength
Biodegradable implant concept	Reduced if foundational claims have expired
Specific PLGA-dexamethasone composition	Depends on claim scope and remaining term
Release-profile claims	Potentially strong if difficult to design around
Applicator claims	Relevant to device-copying risk
Method-of-use claims	Useful where indications remain commercially important
Manufacturing claims	Stronger when process parameters are difficult to replicate
Trade secrets	Potentially durable but harder to enforce against independent development

The highest-value surviving protection is likely to be the combination of formulation, release behavior, applicator configuration, and manufacturing know-how. A competitor may avoid a composition claim but still face practical difficulty reproducing the clinical release profile.

What is the best excipient strategy for a follow-on OZURDEX product?

A follow-on sponsor should prioritize a polymer and process strategy that creates measurable performance differentiation.

Recommended priorities are:

• Select a PLGA grade with reproducible degradation kinetics.
• Establish a design space for molecular weight, moisture, and end-group chemistry.
• Use in vitro release testing linked to in vivo exposure.
• Control implant geometry and surface characteristics.
• Validate sterilization impact on polymer molecular weight.
• Develop an applicator that reduces deployment variability.
• Generate comparative ophthalmic safety data.
• Map the formulation against Orange Book patents and related patent families.
• Consider a 505(b)(2) strategy if exact equivalence is impractical.
• Seek freedom to operate around method-of-use and device claims.

The commercial objective should be a product that is easier to manufacture, safer to administer, or more flexible in retreatment than the reference product. A chemically identical implant without a credible cost or patent advantage is unlikely to justify the development burden.

Key Takeaways

• OZURDEX uses PLGA as a functional biodegradable matrix for sustained intravitreal dexamethasone release.
• The commercial opportunity is concentrated in specialized PLGA supply, implant manufacturing, applicators, and follow-on sustained-release products.
• The product is a small-molecule drug-device combination, so biosimilar competition is not the relevant pathway.
• Generic and 505(b)(2) competition may face substantial equivalence, release-testing, sterility, and applicator challenges.
• Patent analysis must separate Orange Book-listed patents from broader formulation, device, method-of-use, foreign, and manufacturing patent families.
• Trade secrets and manufacturing know-how may remain important after foundational patent expiration.
• The strongest follow-on strategy is a differentiated implant with improved duration control, safety, delivery, or manufacturing economics.

FAQs

Can PLGA be replaced in an OZURDEX follow-on product?

Yes. A sponsor could use another biodegradable polymer or a modified PLGA composition, but the change would affect release kinetics, degradation, safety, manufacturing, and regulatory requirements.

Is the OZURDEX implant preservative-free?

Yes. The product is a solid biodegradable implant rather than a multi-dose liquid ophthalmic formulation. Preservative control is therefore handled differently from conventional eye drops or injectable suspensions.[1]

Can a generic company use a different applicator?

Potentially. The alternative applicator must deliver the implant reliably and satisfy FDA requirements for the drug-device combination. It must also avoid applicable device patent claims.

Does a different PLGA ratio automatically avoid OZURDEX patents?

No. Patent scope depends on the claim language. A different lactide:glycolide ratio may avoid one claim while remaining within another composition, release-profile, device, or method-of-use claim.

Is a longer-lasting dexamethasone implant commercially attractive?

Yes, if it reduces injection burden without materially increasing intraocular pressure, cataract, inflammation, migration, or other ocular risks. The principal development challenge is balancing duration against dose control and safety.

References

1. U.S. Food and Drug Administration. (2023). OZURDEX (dexamethasone intravitreal implant) prescribing information.
2. U.S. Food and Drug Administration. (2009). OZURDEX approval letter and regulatory review materials.
3. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,767,830, Biodegradable implants for treating ocular conditions.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. AbbVie Inc. (2024). Annual report and securities filings.